Dexamethasone
DrugDexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.
Other names: OZURDEX®
NCT Number: NCT02121262
This study will evaluate the safety and efficacy of 700 μg dexamethasone versus laser photocoagulation in participants with diabetic macular edema (DME).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Beijing Friendship Hospital of Capital Medical University, Beijing, Beijing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.
Other names: OZURDEX®
Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
Time frame: Baseline to Month 12
BCVA was measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The eligible eye with worse visual acuity was selected as the study eye. The average change was computed by subtracting the baseline BCVA from the area under the BCVA curve (AUC) divided by the total follow-up time for each participant. Analysis of covariance (ANCOVA) model was used for the analysis.
Time frame: Baseline to Month 12
BCVA was measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The eligible eye with worse visual acuity was selected as the study eye.
Time frame: Baseline to Month 12
CRT was assessed using SD-OCT, a non-invasive diagnostic system that provides high-resolution imaging sections of the retina. SD-OCT is performed in the study eye after pupil dilation. A negative change from Baseline indicates improvement and a positive change from baseline indicates worsening. The eligible eye with worse visual acuity was selected as the study eye. ANCOVA model was used for the analysis.
Time frame: Baseline to Month 12
FA is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Early and transit images were taken of the study eye. Mid- and late-phase images were taken of the study and non-study eye. Electronic FA images were collected for evaluation by a reading center. The eligible eye with worse visual acuity was selected as the study eye. ANCOVA model was used for the analysis.
Allergan
Industry
Dexamethasone Posterior Segment Drug Delivery System Versus Laser Photocoagulation in Patients With Diabetic Macular Edema
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06011798
Cardiovascular Diseases, Diabetes Complications
Bakersfield, California, United States
View Trial DetailsNCT07090044
Cardiovascular Diseases, Choroid Diseases
St Louis, Missouri, United States
View Trial DetailsNCT04635800
Cardiovascular Diseases, Diabetic Macular Edema
Huntington Beach, California, United States
View Trial DetailsNCT03751501
Cardiovascular Diseases, Diabetes Complications
Paris, France
View Trial Details